Natera specializes in cell-free DNA testing to elevate the science and utility of prenatal testing.
Natera specializes in cell-free DNA testing is driven by a passion for elevating the science and utility of prenatal testing. The advent of the Information Age has created a paradigm shift in the fields of computing and informatics. Surprisingly, medical diagnostics have been slow to integrate these advances into genetic testing.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 15, 2022 | Post-IPO Equity | $400.05M | — | — | — | Detail |
| Mar 16, 2022 | Post-IPO Equity | $5M | 2 |
Matthew Rabinowitz
Roelof Botha
|
— | Detail |
| Apr 13, 2020 | Post-IPO Equity | $250M | — | — | — | Detail |
| Jul 10, 2015 | IPO | — | — | — | — | Detail |
| Apr 6, 2015 | Series F | $55.50M | 7 |
Sofinnova Investments
|
— | Detail |
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Jun 21, 2022
Myome
|
Series B | $23M | Biotechnology | — |
|
Jun 30, 2021
Kriptomat
|
Seed | €2.20M | Blockchain | — |
|
Dec 7, 2016
doctoranytime
|
Angel | €1M | Beauty | — |
|
Aug 2, 2015
Blueground
|
Seed | $189.64K | Hospitality | — |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Matthew Rabinowitz
|
Yes | Post-IPO Equity |
Roelof Botha
|
Yes | Post-IPO Equity |
Sofinnova Investments
|
Yes | Series F |
|
|
Yes | Series E |
Sequoia Capital
|
— | Series F |
Franklin Templeton Investments
|
— | Series F |
HealthCor Partners
|
— | Series F |
Jennison Associates
|
— | Series F |
OrbiMed
|
— | Series F |
RA Capital Management
|
— | Series F |